دورية أكاديمية
Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study
| العنوان: | Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study |
|---|---|
| المؤلفون: | Di Iorio B. R., Bellasi A., Raphael K. L., Santoro D., Aucella F., Garofano L., Ceccarelli M., Di Lullo L., Capolongo G., Di Iorio M., Guastaferro P., Capasso G., Barbera V., Bruzzese A., Canale V., Conte G., Crozza V., Cupisti A., DeBlasio A., DeSimone E., DiMicco L., Fiorini F., Grifa R., Nardone R., Piemontese M., Sirico M. L., Vitale F. |
| المساهمون: | Di Iorio, B. R., Bellasi, A., Raphael, K. L., Santoro, D., Aucella, F., Garofano, L., Ceccarelli, M., Di Lullo, L., Capolongo, G., Di Iorio, M., Guastaferro, P., Capasso, G., Barbera, V., Bruzzese, A., Canale, V., Conte, G., Crozza, V., Cupisti, A., Deblasio, A., Desimone, E., Dimicco, L., Fiorini, F., Grifa, R., Nardone, R., Piemontese, M., Sirico, M. L., Vitale, F. |
| سنة النشر: | 2019 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | Chronic kidney disease, Metabolic acidosi, Sodium bicarbonate |
| الوصف: | Background: Metabolic acidosis is associated with accelerated progression of chronic kidney disease (CKD). Whether treatment of metabolic acidosis with sodium bicarbonate improves kidney and patient survival in CKD is unclear. Methods: We conducted a randomized (ratio 1:1). open-label, controlled trial (NCT number: NCT01640119. www.clinicaltrials.gov) to determine the effect in patients with CKD stage 3–5 of treatment of metabolic acidosis with sodium bicarbonate (SB) on creatinine doubling (primary endpoint), all-cause mortality and time to renal replacement therapy compared to standard care (SC) over 36-months. Parametric, non-parametric tests and survival analyses were used to assess the effect of SB on these outcomes. Results: A total of 376 and 364 individuals with mean (SD) age 67.8 (14.9) years, creatinine clearance 30 (12) ml/min, and serum bicarbonate 21.5 (2.4) mmol/l were enrolled in SB and SC, respectively. Mean (SD) follow-up was 29.6 (9.8) vs 30.3 (10.7) months in SC and SB. respectively. The mean (SD) daily doses of SB was 1.13 (0.10). 1.12 (0.11). and 1.09 (0.12) mmol/kg*bw/day in the first, second and third year of follow-up, respectively. A total of 87 participants reached the primary endpoint [62 (17.0%) in SC vs 25 (6.6%) in SB, p < 0.001). Similarly, 71 participants [45 (12.3%) in SC and 26 (6.9%) in SB, p = 0.016] started dialysis while 37 participants [25 (6.8%) in SC and 12 (3.1%) in SB, p = 0.004] died. There were no significant effect of SB on blood pressure, total body weight or hospitalizations. Conclusion: In persons with CKD 3–5 without advanced stages of chronic heart failure, treatment of metabolic acidosis with sodium bicarbonate is safe and improves kidney and patient survival. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31598912; info:eu-repo/semantics/altIdentifier/wos/WOS:000498618400014; volume:32; issue:6; firstpage:989; lastpage:1001; numberofpages:13; journal:JN. JOURNAL OF NEPHROLOGY; https://hdl.handle.net/11568/1018664Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85074011152; http://www.springer.com/medicine/nephrology/journal/40620Test |
| DOI: | 10.1007/s40620-019-00656-5 |
| الإتاحة: | https://doi.org/10.1007/s40620-019-00656-5Test https://hdl.handle.net/11568/1018664Test http://www.springer.com/medicine/nephrology/journal/40620Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.923828FA |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s40620-019-00656-5 |
|---|